Forbes "Vertex Scores A Big Win With Cystic Fibrosis // LINK
Vertex Scores A Big Win With Cystic Fibrosis
As a result, analysts are quickly increasing their outlook for the biotech. For instance, Robyn Karnauskas of Deutsche Bank says the results greatly bolster the likelihood that Vertex will be able to treat most patientwith the F508del mutation. Moreover, she adds, the results “increase the market size opportunity for (treating) other mutations,” as well, she wrote in an investor note.Karnauskas adds that “we think that data available so far on Vertex drugs is truly suggesting that the company has a cystic fibrosis franchise technology.